Rectal Cancer
Conditions
Interventions
Control group (Standard nutritional support):NA
Interventional group (Traditional Chinese medicine+standard nutrition support):NA
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age = 18 years old. (2) Pathological diagnosis was rectal adenocarcinoma. (3) Local advanced stage (T3-T4 or N+) was diagnosed by CT, MRI and/or endoscopic ultrasonography. (4) Subjects must have good organ functions and be evaluated according to the following laboratory examination results: Absolute neutrophil count (ANC) of blood system = 1.5 × 10~9/L Platelet = 70 × 10~9/L Hemoglobin = 90 g/L or = 5.6 mmol/L Renal serum creatinine = 1.5 × ULN or serum creatinine clearance = 40 mL/min Total bilirubin of liver = 1.5 × ULN AST= 2.5 × ULN ALT= 2.5 × ULN International normalized coagulation ratio (INR) = 1.5 × ULN Prothrombin time (PT) = 1.5 × ULN (5) Men with fertility and women of childbearing age must agree to take effective contraceptive measures within 180 days from the signing of the informed consent to the end of concurrent radiotherapy and chemotherapy. Women of childbearing age include premenopausal women and women within 2 years after menopause. Pregnancy must be excluded for women of childbearing age before concurrent radiotherapy and chemotherapy.
Exclusion criteria
Exclusion criteria: (1) Patients with severe bleeding tendency and severe infection. (2) Patients who cannot cooperate with continuous follow-up. (3) Other primary malignant tumors occurred within 5 years before concurrent radiotherapy and chemotherapy, except for locally curable malignant tumors after radical treatment (such as basal or squamous cell skin cancer, superficial bladder cancer or prostate, cervical or breast cancer in situ). (4) Have uncontrollable concomitant diseases, including but not limited to symptomatic congestive heart failure, uncontrollable hypertension, unstable angina pectoris, arrhythmia, active peptic ulcer or hemorrhagic disease. (5) Patients with a history of alcohol or drug abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor Degradation Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Cancer Specific Survival;Disease-free Suvival; | — |
Countries
China
Contacts
Public ContactHao Wang
Peking University Third Hospital
Outcome results
None listed